Shares of Cipher Pharmaceuticals (TSE:CPH) are crossing below their fifty-day moving average of $14.21

Shares of Cipher Pharmaceuticals Inc. (TSE:CPH – Get Your Free Report ) (NASDAQ:CPHR) moved below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $14.21 and traded at $14.21. Shares of Cipher Pharmaceuticals last traded at $14.50, with a volume of 53,800 shares traded.

Analyst upgrades and downgrades

Several research firms have weighed in on CPH. Stifel Canada raised Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th. Stifel Nicolaus raised shares of Cipher Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price target for the company from $9.50 to $16.00 in a research note on Tuesday. August 13. Finally, Leede Financial cut shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 13th.

Check out our latest research report on Cipher Pharmaceuticals

Cipher Pharmaceuticals stock down 2.0%

The stock has a market cap of $371.06 million, a price-to-earnings ratio of 11.79 and a beta of 1.25. The firm has a 50-day moving average of $14.21 and a 200-day moving average of $10.57. The company has a current ratio of 11.18, a quick ratio of 2.67, and a debt-to-equity ratio of 0.33.

Cipher Pharmaceuticals (TSE:CPH – Get Your Free Report ) (NASDAQ:CPHR) last released its earnings results on Thursday, August 8th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.15 by $0.01. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. The company had revenue of $7.26 million during the quarter, compared to analysts’ expectations of $7.52 million. On average, sell-side analysts anticipate that Cipher Pharmaceuticals Inc. will post 1.4156977 earnings per share for the current year.

About Cipher Pharmaceuticals

(Get a free report)

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. Offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, conglomerate acne, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of mildly palpable and/or moderately thick (grade I/II) hyperkeratotic actinic keratosis of the face, forehead and bald scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream to slow the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for rapid conversion of early-onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome.

Further reading

Get daily news and reviews for Cipher Pharmaceuticals – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.